{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-048292","form_type":"8-K","ticker":"LIXT","cik":"0001335105","company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","filed_at":"2024-12-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.207422+00:00","generated_at":"2026-05-29T10:59:58.145004+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Lixte pauses NKI/Oncode collaboration until Phase 1b trial starts; budget cut to €100K","bullets":["Amendment 3 pauses research activities under the development collaboration with NKI and Oncode Institute.","Collaboration resumes upon first patient dosing in Phase 1b trial combining LB-100 with a WEE1 inhibitor in metastatic colorectal cancer.","Termination date revised to one year from first patient dosing; annual budget reduced from €250,000 to €100,000.","Parties will study translational data from patient samples in NKI clinical trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-048292","json":"https://secwatch.observer/filing/0001493152-24-048292.json","markdown":"https://secwatch.observer/filing/0001493152-24-048292.md","text":"https://secwatch.observer/filing/0001493152-24-048292.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1335105/000149315224048292/0001493152-24-048292-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1335105/000149315224048292/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T10:59:58.145004+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}